Investing.com — Processa Pharmaceuticals Inc. (PCSA)股价已跌至52周新低，触及$0.36。这一显著下跌反映了公司正经历艰难时期，过去一年股价暴跌了-84.39%。根据 InvestingPro 数据，公司市值已萎缩至仅220万美元，而在过去十二个月中录得负EBITDA为-1205万美元。投资者一直密切关注公司表现，这一新低点标志着对其未来前景和市 ...

Processa Pharmaceuticals (NASDAQ:PCSA – Get Free Report) last posted its quarterly earnings data on Thursday, March 20th. The company reported ($0.74) EPS for the quarter, beating analysts ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Talphera (TLPH – Research Report) and Cardiol ...

This article was generated by Benzinga's automated content engine and reviewed by an editor.

IPC Indice de Precios Y Cotizaciones 53,337.90 853.47 1.63% ...

Mar. 18, 2025 — A research team has found that lecanemab was probably less effective in females than males in its Phase 3 trial. However, there was insufficient evidence to say the drug was ...

U.S. flag and medicines are seen in this illustration taken, June 27, 2024. REUTERS/Dado Ruvic/Illustration/File Photo Drugmaker stocks gained a temporary reprieve on Thursday as U.S. President ...

Healthcare & Pharmaceuticalscategory· March 14, 2025 Drugmakers agree to participate in second round of price negotiations All drug manufacturers, including Novo Nordisk and Teva Pharmaceuticals ...

Delivering late stage therapeutic pipeline, building the next generation of radiopharmaceuticals, growing industry leading precision medicine business, expanding global infrastructure for product ...

Biopharmaceutical company developing drugs for neurological disorders.